# Clinical Trials Network New England Consortium Node: Admin Supplement CTN0131

> **NIH NIH UG1** · YALE UNIVERSITY · 2022 · $1,638,420

## Abstract

We will conduct a randomized, pragmatic hybrid type 1 effectiveness/implementation multisite (approximately 6
sites) trial to determine whether office-based methadone with pharmacy administration and/or dispensing or
buprenorphine (BUP) results in greater treatment retention in approximately 600 patients with opioid use disorder
(OUD) not optimally benefiting from office-based BUP. As part of the trial, we will identify implementation barriers
and facilitators at the patient, provider and health-systems level for office-based methadone with pharmacy
administration and/or dispensing.

## Key facts

- **NIH application ID:** 10655837
- **Project number:** 3UG1DA015831-21S6
- **Recipient organization:** YALE UNIVERSITY
- **Principal Investigator:** Gail D'Onofrio
- **Activity code:** UG1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $1,638,420
- **Award type:** 3
- **Project period:** 2022-08-01 → 2023-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10655837

## Citation

> US National Institutes of Health, RePORTER application 10655837, Clinical Trials Network New England Consortium Node: Admin Supplement CTN0131 (3UG1DA015831-21S6). Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/grant/nih/10655837. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*